Making the Call in Heart Failure

Multidimensional Outcomes with SGLT2 Inhibitors

CLINICAL RESOURCE CENTER

Use the QR Code or URL to access the program slides, accreditation and disclosure information, as well as the clinical resource center.

www.ExchangeCME.com/HeartFailureResources This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from AstraZeneca.

This event is not part of the official Scientific Sessions Conference 2022 as planned by the AHA Committee on Scientific Sessions Programming.

BIYKEM BOZKURT, MD, PhD, FHFSA, FACC, FAHA, FACP

Dr. Biykem Bozkurt is an advanced heart failure and cardiac transplantation specialist at Baylor College of Medicine (BCM) in Houston, Texas, where she serves as the Associate Provost of Faculty Affairs, Senior Associate Dean of Faculty Development, Mary and Gordon Cain Chair in Cardiology, Professor of Medicine, Director of Winters Center for Heart Failure, W. A. “Tex” and Deborah Moncrief, Jr. Chair in Cardiology, Associate Director of the Cardiovascular Research Institute, and Vice-Chair of Department of Medicine. Dr. Bozkurt is the Editor-in-Chief of Journal of the American College of Cardiology (JACC): Heart Failure. She has served as the co-chair of the 2022 American Heart Association (AHA)/American College of Cardiology (ACC) Heart Failure Guidelines Writing Committee, past President of the Heart Failure Society of America, and leader of the Universal Definition and Classification of Heart Failure.

Throughout her career, Dr. Bozkurt has been recognized for excellence in clinical care, education, and leadership. She received the ACC Gifted Educator Award in 2016 as well as Presidential awards in Education and Master Clinician awards from Baylor College of Medicine, and has been listed in Clarivate World’s Highly Cited Researchers (top 1% Web of Science).

Dr. Bozkurt actively participates in clinical and translational research; presents at national and international scientific sessions; teaches medical students, residents, fellows at bedside and in the classroom setting; mentors trainees and faculty.

JAVED BUTLER, MD, MPH, MBA

Dr. Javed Butler is the President of the Baylor Scott and White Research Institute and Senior Vice President for Baylor Scott and White Health. He is also Distinguished Professor of Medicine at University of Mississippi in Jackson, Mississippi. Prior to joining Baylor Scott and White Health, he served as the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi, where he was also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University in New York. He had served as the director for heart failure research at Emory University in Atlanta, Georgia, and director of the heart and heart-lung transplant programs at Vanderbilt University in Nashville, Tennessee, prior to that.

Dr. Butler received his medical degree from the Aga Khan University in Karachi, Pakistan, and then completed his residency at Yale University in New Haven, Connecticut, a cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and a cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School in Boston. He also earned a Master of Public Health degree from Harvard University and a Master in Business Administration from Emory University.

Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine.

His research has focused on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and Heart Failure Society of America. He received the Simon Dack Award from the American College of Cardiology as well as the Time, Feeling, and Focus Award from the American Heart Association.

Dr. Butler has authored more than 875 peer-reviewed publications. He serves on the editorial board of several peer-reviewed cardiovascular journals and has been cited numerous times in the America’s Best Doctors list.

The Mary and Gordon Cain Chair and Professor of Medicine Associate Provost of Faculty Affairs, Senior Associate Dean of Faculty Development Director, Winters Center for Heart Failure Research Baylor College of Medicine Houston, Texas

President, Baylor Scott and White Research Institute Dallas, Texas Distinguished Professor of Medicine University of Mississippi Jackson, Mississippi

CHRISTOPHER P. CANNON, MD Education Director Cardiovascular Medicine Innovation Preventive Cardiology Section, Brigham and Women’s Hospital Remote faculty, Clinician-Scientist CPC Clinical Research Professor of Medicine, Harvard Medical School Boston, Massachusetts

Dr. Christopher Cannon is a Professor of Medicine at Harvard Medical School and senior physician in the Preventive Cardiology section of the Cardiovascular Division at Brigham and Women’s Hospital. He serves as Education Director in the Cardiovascular Medicine Innovation group and has recently joined the remote faculty as a Clinician Scientist at the CPC Clinical Research Institute in Aurora, Colorado. Previously, he worked for 25 years as an investigator in the TIMI [thrombolysis in myocardial infarction] Study Group, then for 9 years at the Harvard Clinical Research Institute/Baim Institute.

He earned his medical degree from Columbia University College of Physicians and Surgeons in New York, New York, his internal medicine residency at Columbia Presbyterian Medical Center, and his cardiovascular fellowship at Brigham and Women’s Hospital.

Dr. Cannon has published over 1000 original articles, reviews, or book chapters in the field of acute coronary syndromes and prevention and has authored or edited 20 books. He has received numerous awards, including leadership awards from the American College of Cardiology, American Heart Association, and National Lipid Association.

Former principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, RE-DUAL PCI, and VERTIS CV trials, Dr. Cannon is currently working on clinical trials, registries, and quality improvement projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids, and prevention. In his role at Cardiovascular Medicine Innovation, he helps implement quality improvement programs using telemedicine for lipids, hypertension, and diabetes, and at CPC Clinical Research he helps lead pragmatic clinical trials.

“CALL-A-COLLEAGUE” CONSULTANTS GEORGE BAKRIS, MD

Professor of Medicine Section of Endocrinology, Diabetes, and Metabolism Director, AHA Comprehensive Hypertension Center University of Chicago Medicine Chicago, Illinois

CYNTHIA CHAUHAN Patient

ALICE Y. Y. CHENG, MD, FRCPC Endocrinologist Trillium Health Partners & Unity Health Toronto Associate Professor, University of Toronto Toronto, Canada

TARGET AUDIENCE

AGENDA

The educational design of this activity addresses the needs of cardiologists and other specialist clinicians with a focus on heart failure.

6:00 am

Faculty Introduction and Preactivity Questions

6:10 am

Overview of New Heart Failure Recommendations

PROGRAM OVERVIEW

6:30 am Pathophysiology of Heart Failure, Including Insights Into the Mechanism of SGLT2 Inhibitors Clinical Review of Efficacy of SGLT2 Inhibitors in Heart Failure Clinical Review of Renoprotective Outcomes With SGLT2 Inhibitors

Heart failure medicine is dynamic, with recent approvals for use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, and updated recommendations for definition, staging, and classification of heart failure. As heart failure therapies overlap into other specialties, it is more important than ever to use a patient-centered, multidisciplinary care team model. In this 90-minute Call-a-Colleague presentation, 3 experts will discuss the new consensus recommendations for heart failure and the evidence for using SGLT2 inhibitors in patients with different classes of heart failure as well as comorbidities. To illustrate how to individualize treatment regimens and the nuances of heart failure care, they will call in specialist colleagues for consultations about practical considerations for prescribing SGLT2 inhibitors.

EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to: • Evaluate patients with heart failure based on new consensus recommendations for definition, staging, and classification • Discuss the clinical profiles, trial designs, and recent data for SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), including cardiovascular and renal outcomes • Incorporate SGLT2 inhibitors into treatment algorithms for heart failure to reflect appropriate patient selection, safety considerations, and prescribing recommendations • Individualize treatment regimens for patients with heart failure with consideration of case presentation, practice guidelines, newly published evidence, and comorbidities, such as chronic kidney disease (CKD)

PHYSICIAN ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

7:00 am

Comprehensive Management of Patients With Heart Failure – From the Patient and Clinician Perspectives Consultations with nephrology and endocrinology colleagues as well as a patient included to illustrate multidisciplinary care

7:20 am

Postactivity Questionnaire and Audience Q&A

PHYSICIAN CREDIT DESIGNATION Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.5 contact hours is provided by Global Education Group.

Nurses should claim only the credit commensurate with the extent of their participation in the activity.

GLOBAL CONTACT INFORMATION For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

INSTRUCTIONS TO RECEIVE CREDIT Participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and submit the evaluation form directly after the activity.

FEE INFORMATION & REFUND/CANCELLATION POLICY There is no fee for this educational activity.

Christopher P. Cannon, MD

Consulting fees: Aegerion/Amryt, Alnylam Pharmaceuticals, Inc., Amarin Corporation, Amgen Inc., Applied Therapeutics, Ascendia Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., Rhoshan Pharmaceuticals, Sanofi S.A. Contracted Research: Amgen Inc., Better Therapeutics, Inc, Boehringer Ingelheim, Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc.

George Bakris, MD (Consultant)

Consulting fees: Alnylam Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals, Bayer AG, DiaMedica Therapeutics, Inc., inRegen, Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, KBP Biosciences Co., Ltd., Novo Nordisk A/S, Quantum Genomics SA Contracted Research: Bayer AG, Novo Nordisk A/S

DISCLOSURES OF CONFLICTS OF INTEREST Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies: Biykem Bozkurt, MD, Consulting fees and Contracted research: Abbott Vascular, PhD, FHFSA, FACC, AstraZeneca Pharmaceuticals, Baxter, Cardurion, Liva Nova, FAHA, FACP Renovacor, Respicardia, Sanofi Aventis Pharmaceuticals, Vifor Javed Butler, MD, MPH, MBA

Consulting fees: Abbott, Adrenomed AG, Amgen Inc., Applied Therapeutics, Array BioPharma, AstraZeneca Pharmaceuticals, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb Company, CVRx, G3 Pharmaceuticals Inc., Impulse Dynamics N.V., Innolife Co., Ltd., Janssen Pharmaceuticals, LivaNova PLC, Luitpold Pharmaceuticals, Inc., Medtronic plc, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Relypsa, Inc., Roche, Vifor Pharma Group.

Speakers’ Bureaus: AstraZeneca Pharmaceuticals, Boehringer Ingelheim, Eli Lilly and Company, Janssen Pharmaceuticals, Novartis Pharmaceuticals Corporation.

Alice Y.Y. Cheng, MD, Consulting Fees: Abbott, AstraZeneca Pharmaceuticals, Bayer FRCPC (Consultant) AG, Boehringer Ingelheim, Dexcom, Inc., Eisai Co., Ltd., Eli Lilly and Company, Insulet Corporation, HLS Therapeutics, Inc., Janssen Pharmaceuticals, Novo Nordisk A/S, Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc. Honoraria: Abbott, Amgen Inc., AstraZeneca Pharmaceuticals, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim, Dexcom, Inc., Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline, Insulet Corporation, HLS Therapeutics, Inc., Janssen Pharmaceuticals, Medtronic plc, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals U.S.A., Inc. Speakers’ Bureaus: Abbott, Amgen Inc., AstraZeneca Pharmaceuticals, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim, Dexcom, Inc., Eli Lilly and Company, GlaxoSmithKline, Insulet Corporation, HLS Therapeutics, Inc., Janssen Pharmaceuticals, Medtronic plc, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. Cynthia Chauhan (Patient)

Honoraria: Astellis

The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

DISCLAIMER

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Integritas do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.